The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...

Semaglutide associated with increased walking distance in patients with symptomatic peripheral artery disease and type 2 diabetes.

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients ...

USA: The STRIDE trial has demonstrated that semaglutide significantly enhances walking capacity in individuals with ...

Among patients with diabetes and peripheral artery disease, semaglutide 1 mg increased walking distance vs. placebo, ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

The results of the clinical trial show that Semaglutide improved quality of life and increased the distance that participants ...